ILDong: Ildong jumps into GERD market with p-1 trial of P-CAB drug

Ildong Pharmaceutical has jumped into developing P-CAB (potassium-competitive acid blockers)-based treatment for gastroesophageal reflux disease (GERD), drawing the industry's attention to the market once again.Last Thursday, the Ministry of Food and Drug Safety approved the domestic phase 1 trial o